Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q1
Quarterly report
1 Nov 23
10-Q
2023 Q1
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2023 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
4 Mar 24
8-K
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 Feb 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
9 Jan 24
8-K
Regulation FD Disclosure
12 Dec 23
8-K
Entry into a Material Definitive Agreement
12 Dec 23
8-K
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
20 Nov 23
8-K
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
1 Nov 23
8-K
C4 Therapeutics Announces Chief Financial Officer Succession
5 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
22 Feb 24
S-8
Registration of securities for employees
23 Feb 23
POS AM
Prospectus update (post-effective amendment)
23 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
23 Feb 23
S-8
Registration of securities for employees
24 Feb 22
S-3ASR
Automatic shelf registration
10 Nov 21
424B4
Prospectus supplement with pricing info
21 Jun 21
S-1
IPO registration
14 Jun 21
DRS
Draft registration statement
19 May 21
S-8
Registration of securities for employees
11 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
17 Jun 22
DEFA14A
Additional proxy soliciting materials
12 May 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEF 14A
Definitive proxy
26 Apr 21
Other
EFFECT
Notice of effectiveness
4 May 23
EFFECT
Notice of effectiveness
17 Jun 21
CORRESP
Correspondence with SEC
14 Jun 21
CORRESP
Correspondence with SEC
14 Jun 21
UPLOAD
Letter from SEC
21 May 21
EFFECT
Notice of effectiveness
2 Oct 20
CERT
Certification of approval for exchange listing
1 Oct 20
CORRESP
Correspondence with SEC
29 Sep 20
CORRESP
Correspondence with SEC
29 Sep 20
SEC STAFF
SEC staff action: Order
28 Sep 20